Tumor-enriched proteases (such as matrix metalloproteinase-2 [MMP2], MMP9, and urokinase plasminogen activator [uPA]3) can cleave the linker and release hemagglutinin (HA)-tagged IL-15 within the TME. The gene discussed is MMP2; the disease is neoplasm.